150 related articles for article (PubMed ID: 34837957)
21. Extrapolation of Survival Data Using a Bayesian Approach: A Case Study Leveraging External Data from Cilta-Cel Therapy in Multiple Myeloma.
Palmer S; Lin Y; Martin TG; Jagannath S; Jakubowiak A; Usmani SZ; Buyukkaramikli N; Phelps H; Slowik R; Pan F; Valluri S; Pacaud L; Jackson G
Oncol Ther; 2023 Sep; 11(3):313-326. PubMed ID: 37270762
[TBL] [Abstract][Full Text] [Related]
22. Challenges with Estimating Long-Term Overall Survival in Extensive Stage Small-Cell Lung Cancer: A Validation-Based Case Study.
Johal S; Brannman L; Genestier V; Cawston H
Clinicoecon Outcomes Res; 2024; 16():97-109. PubMed ID: 38433888
[TBL] [Abstract][Full Text] [Related]
23. Value of External Data in the Extrapolation of Survival Data: A Study Using the NJR Data Set.
Pennington M; Grieve R; der Meulen JV; Hawkins N
Value Health; 2018 Jul; 21(7):822-829. PubMed ID: 30005754
[TBL] [Abstract][Full Text] [Related]
24. SurvInt: a simple tool to obtain precise parametric survival extrapolations.
Gallacher D
BMC Med Inform Decis Mak; 2024 Mar; 24(1):76. PubMed ID: 38486175
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of Flexible Parametric Relative Survival Approaches for Enforcing Long-Term Constraints When Extrapolating All-Cause Survival.
Lee S; Lambert PC; Sweeting MJ; Latimer NR; Rutherford MJ
Value Health; 2024 Jan; 27(1):51-60. PubMed ID: 37858887
[TBL] [Abstract][Full Text] [Related]
26. A Flexible Ensemble Learning Method for Survival Extrapolation.
Dai R; Ma J; Wu M; Mai Y; He W
Ther Innov Regul Sci; 2023 May; 57(3):580-588. PubMed ID: 36536263
[TBL] [Abstract][Full Text] [Related]
27. A Review of Overall Survival Extrapolations of Immune-Checkpoint Inhibitors Used in Health Technology Assessments by the French Health Authorities.
Grumberg V; Roze S; Chevalier J; Borrill J; Gaudin AF; Branchoux S
Int J Technol Assess Health Care; 2022 Mar; 38(1):e28. PubMed ID: 35331347
[TBL] [Abstract][Full Text] [Related]
28. Impact of Extrapolation Model Choices on the Structural Uncertainty in Economic Evaluations for Cancer Immunotherapy: A Case Study of Checkmate 067.
Shao T; Zhao M; Liang L; Shi L; Tang W
Pharmacoecon Open; 2023 May; 7(3):383-392. PubMed ID: 36757569
[TBL] [Abstract][Full Text] [Related]
29. Assessing the Performance of Alternative Methods for Estimating Long-Term Survival Benefit of Immuno-oncology Therapies.
Monnickendam G
Value Health; 2024 Feb; ():. PubMed ID: 38428815
[TBL] [Abstract][Full Text] [Related]
30. Comparing Survival Extrapolation within All-Cause and Relative Survival Frameworks by Standard Parametric Models and Flexible Parametric Spline Models Using the Swedish Cancer Registry.
Chen EY; Leontyeva Y; Lin CN; Wang JD; Clements MS; Dickman PW
Med Decis Making; 2024 Apr; 44(3):269-282. PubMed ID: 38314657
[TBL] [Abstract][Full Text] [Related]
31. Survival Analysis in Patients with Metastatic Merkel Cell Carcinoma Treated with Avelumab.
Lanitis T; Proskorovsky I; Ambavane A; Hunger M; Zheng Y; Bharmal M; Phatak H
Adv Ther; 2019 Sep; 36(9):2327-2341. PubMed ID: 31350728
[TBL] [Abstract][Full Text] [Related]
32. How Uncertain is the Survival Extrapolation? A Study of the Impact of Different Parametric Survival Models on Extrapolated Uncertainty About Hazard Functions, Lifetime Mean Survival and Cost Effectiveness.
Kearns B; Stevens J; Ren S; Brennan A
Pharmacoeconomics; 2020 Feb; 38(2):193-204. PubMed ID: 31761997
[TBL] [Abstract][Full Text] [Related]
33. Integrating expert opinion with clinical trial data to extrapolate long-term survival: a case study of CAR-T therapy for children and young adults with relapsed or refractory acute lymphoblastic leukemia.
Cope S; Ayers D; Zhang J; Batt K; Jansen JP
BMC Med Res Methodol; 2019 Sep; 19(1):182. PubMed ID: 31477025
[TBL] [Abstract][Full Text] [Related]
34. Extrapolation of Survival Curves from Cancer Trials Using External Information.
Guyot P; Ades AE; Beasley M; Lueza B; Pignon JP; Welton NJ
Med Decis Making; 2017 May; 37(4):353-366. PubMed ID: 27681990
[TBL] [Abstract][Full Text] [Related]
35. Survival extrapolation in the presence of cause specific hazards.
Benaglia T; Jackson CH; Sharples LD
Stat Med; 2015 Feb; 34(5):796-811. PubMed ID: 25413028
[TBL] [Abstract][Full Text] [Related]
36. An Evaluation of Survival Curve Extrapolation Techniques Using Long-Term Observational Cancer Data.
Vickers A
Med Decis Making; 2019 Nov; 39(8):926-938. PubMed ID: 31631772
[No Abstract] [Full Text] [Related]
37. Novel and existing flexible survival methods for network meta-analyses.
Heeg B; Garcia A; Beekhuizen SV; Verhoek A; Oostrum IV; Roychoudhury S; Cappelleri JC; Postma MJ; Nicolaas Martinus Ouwens MJ
J Comp Eff Res; 2022 Sep; ():. PubMed ID: 36093741
[No Abstract] [Full Text] [Related]
38. Extrapolating empirical long-term survival data: the impact of updated follow-up data and parametric extrapolation methods on survival estimates in multiple myeloma.
Bakker LJ; Thielen FW; Redekop WK; Groot CU; Blommestein HM
BMC Med Res Methodol; 2023 May; 23(1):132. PubMed ID: 37248477
[TBL] [Abstract][Full Text] [Related]
39. Estimating the loss of lifetime function using flexible parametric relative survival models.
Jakobsen LH; Andersson TM; Biccler JL; El-Galaly TC; Bøgsted M
BMC Med Res Methodol; 2019 Jan; 19(1):23. PubMed ID: 30691400
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
